Evaluation of the Performance of the IDBIORIV Method in Pathogen Identification and Antibiotic Susceptibility Testing in Patients With Sepsis
Key facts
- Who runs it
- Hospices Civils de Lyon
- Where
- France7 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 1,372 people, planned
- Started
- 21 Mar 2024
- Expected to end
- 21 Nov 2026
- Type of study
- Observational, 3 groups
- Treatments tested
- no intervention - Contamination group
- blood sample - Bacteraemia group
- no intervention - Emergency group
- Record updated
- 10 June 2026
Who can take part
- Age
- 1 day and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Adult or child patient
- Hospitalized in one of the departments registered with Hospices Civils de Lyon
- Showing signs of infection
- Confirmed by a 1st positive blood culture
- Patient or close relative (trustworthy person or family member) or holder of parental authority who has given his or her non-objection after receiving the information note
Who cannot take part
- Patients under court protection
- Patients under guardianship or curatorship
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Sepsis is a disruption of homeostasis in the human body in response to bloodstream infection and is associated with a high risk of mortality.
Read full original descriptionShow less
Worldwide, sepsis is affecting approximately 30 million people and resulting in six million deaths.
Blood culture is a specific blood sample used to identifying microbial agent (bacterium or yeast) and determine the sensitivity of these microorganisms to antibiotics and antifungals.
Any delay in identifying the microorganism and/or determining the AST (antibiotic susceptibility testing) has a direct impact on the administration of appropriate antibiotic treatment and, consequently, on mortality of the patient. The faster the diagnosis, the faster the antibiotic treatment will be adapted, the higher the survival rate/probability of patients, and the lower the ecological impact.
In routine, clinical microbiology laboratories currently use 2 automatized techniques: MALDI-TOF MS® for microorganisms identification and VITEK2® method for AST determination.
Based on a proteomic approach, the IDBIORIV method is a rapid method (90 minutes) in comparison of current methods (24/48 hours) able to identifying a large panel of 113 pathogens and determine the antibiotic resistance profile of 49 species for 4 classes of antibiotics (Beta-lactams, Aminosides, Glycopeptides, Colistin).
The main objective of this study is to evaluate the performance of the IDBIORIV method in pathogen identification and antibiotic susceptibility testing in comparison with current methods of analysis of positive blood cultures used at the microbiology laboratory of the Hospices Civils de Lyon, in a real clinical situation, over a 2-year period.
The 3 groups in the trial
- Contamination
Patients with a positive blood culture due to contamination microorganism
Treatment: no intervention - Contamination group
- Bacteraemia
This group includes all adults and children with a positive blood culture due to pathogen microorganism
Treatment: blood sample - Bacteraemia group
- Emergency
Emergency Room Patient's with a positive blood culture due to pathogen and/or contamination microorganism
Treatment: no intervention - Emergency group
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 10 June 2026